tiprankstipranks
GlaxoSmithKline (CH:GS71)
:GS71
Switzerland Market
GS71
GlaxoSmithKline
RESEARCH TOOLSreports

GlaxoSmithKline (GS71) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

GS71 Analyst Ratings

Hold
14Ratings
Hold
3 Buy
9 Hold
2 Sell
Based on 14 analysts giving stock ratings to
GlaxoSmithKline
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

GS71 Stock 12 Month Forecast

Average Price Target

CHF23.36
▼(-10.58% Downside)
Based on 14 Wall Street analysts offering 12 month price targets for GlaxoSmithKline in the last 3 months. The average price target is CHF23.36 with a high forecast of CHF32.74 and a low forecast of CHF18.49. The average price target represents a -10.58% change from the last price of CHF26.12.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"17":"CHF17","21":"CHF21","25":"CHF25","29":"CHF29","33":"CHF33"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":32.74119975,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF32.74</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.355925207499997,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF23.36</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.4917075,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF18.49</span>\n  </div></div>","useHTML":true}}],"tickPositions":[17,21,25,29,33],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.115,26.624707673076923,27.134415346153844,27.64412301923077,28.153830692307693,28.663538365384614,29.17324603846154,29.68295371153846,30.192661384615384,30.70236905769231,31.21207673076923,31.721784403846154,32.231492076923075,{"y":32.74119975,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.115,25.9027634775,25.690526955,25.4782904325,25.266053909999997,25.053817387499997,24.841580864999997,24.629344342499998,24.41710782,24.2048712975,23.992634775,23.780398252499996,23.568161729999996,{"y":23.355925207499997,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.115,25.52859288461538,24.94218576923077,24.35577865384615,23.769371538461538,23.18296442307692,22.596557307692308,22.01015019230769,21.423743076923078,20.83733596153846,20.250928846153847,19.66452173076923,19.078114615384614,{"y":18.4917075,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":26.115,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.115,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.115,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.115,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.115,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.115,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.115,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.115,"date":1772323200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 20</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.115,"date":1775001600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 21</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.115,"date":1777593600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 18</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.115,"date":1780272000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.115,"date":1782864000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.115,"date":1785542400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetCHF32.74Average Price TargetCHF23.36Lowest Price TargetCHF18.49
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Deutsche Bank Analyst forecast on CH:GS71
Emmanuel Papadakis
Deutsche Bank
Deutsche Bank
CHF21.76
Hold
-16.71%
Downside
Reiterated
08/04/26
Deutsche Bank Keeps Their Hold Rating on GlaxoSmithKline (GSK)
Barclays Analyst forecast on CH:GS71
James Gordon CFA
Barclays
Barclays
CHF20.67
Sell
-20.88%
Downside
Reiterated
08/04/26
GlaxoSmithKline (GSK) Receives a Sell from Barclays
J.P. Morgan Analyst forecast on CH:GS71
Zain Ebrahim
J.P. Morgan
J.P. Morgan
CHF18.49
Sell
-29.20%
Downside
Reiterated
08/04/26
J.P. Morgan Sticks to Their Sell Rating for GlaxoSmithKline (GSK)
Bernstein Analyst forecast on CH:GS71
Justin Smith
Bernstein
Bernstein
CHF30.73→CHF32.74
Buy
25.35%
Upside
Reiterated
08/03/26
Bernstein Sticks to Their Buy Rating for GlaxoSmithKline (GSK)
DZ BANK AG Analyst forecast on CH:GS71
Elmar Kraus
DZ BANK AG
DZ BANK AG
―
Hold
―
Reiterated
07/29/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Crispr Therapeutics AG (NASDAQ: CRSP) and GlaxoSmithKline (LSE: GB:GSK)
Citi Analyst forecast on CH:GS71
Graham Parry
Citi
Citi
CHF22.84
Hold
-12.55%
Downside
Reiterated
07/29/26
Citi Sticks to Their Hold Rating for GlaxoSmithKline (GSK)
Bank of America Securities Analyst forecast on CH:GS71
Sachin Jain
Bank of America Securities
Bank of America Securities
CHF25.56
Hold
-2.13%
Downside
Reiterated
07/28/26
GSK: Hold Rating Reaffirmed as Near-Term Strength Offsets Long-Term Uncertainties; 2,350p Price Target Maintained
Goldman Sachs Analyst forecast on CH:GS71
Rajan Sharma
Goldman Sachs
Goldman Sachs
CHF20.34→CHF20.56
Hold
-21.29%
Downside
Reiterated
07/28/26
GSK: Solid Quarter but Modest Outlook Prompts Hold Rating and Price Target Lift to £18.90
Jefferies Analyst forecast on CH:GS71
Michael Leuchten
Jefferies
Jefferies
CHF27.19
Buy
4.11%
Upside
Reiterated
07/28/26
Jefferies Sticks to Its Buy Rating for GlaxoSmithKline (GSK)
UBS Analyst forecast on CH:GS71
Matthew Weston
UBS
UBS
CHF21.1
Hold
-19.21%
Downside
Reiterated
07/13/26
UBS Remains a Hold on GlaxoSmithKline (GSK)
Guggenheim Analyst forecast on CH:GS71
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
―
Hold
―
Reiterated
07/09/26
Guggenheim Remains a Hold on GlaxoSmithKline (GSK)
HSBC Analyst forecast on CH:GS71
Rajesh Kumar
HSBC
HSBC
CHF16.32→CHF20.23
Hold
-22.54%
Downside
Upgraded
07/06/26
GSK upgraded to Hold from Reduce at HSBCGSK upgraded to Hold from Reduce at HSBC
Intron Health Analyst forecast on CH:GS71
Unknown Analyst
Intron Health
Not Ranked
Intron Health
CHF21.76
Hold
-16.71%
Downside
Upgraded
06/10/26
GlaxoSmithKline (GSK) was upgraded to a Hold Rating at Intron Health
Kepler Capital Analyst forecast on CH:GS71
Nicolas Pauillac
Kepler Capital
Kepler Capital
CHF27.37
Buy
4.78%
Upside
Upgraded
05/26/26
Positive Report for GlaxoSmithKline (GSK) from Kepler Capital
Berenberg Bank Analyst forecast on CH:GS71
Kerry Holford
Berenberg Bank
Berenberg Bank
CHF21.75
Hold
-16.71%
Downside
Reiterated
05/05/26
GlaxoSmithKline (GSK) Receives a Hold from Berenberg Bank
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Deutsche Bank Analyst forecast on CH:GS71
Emmanuel Papadakis
Deutsche Bank
Deutsche Bank
CHF21.76
Hold
-16.71%
Downside
Reiterated
08/04/26
Deutsche Bank Keeps Their Hold Rating on GlaxoSmithKline (GSK)
Barclays Analyst forecast on CH:GS71
James Gordon CFA
Barclays
Barclays
CHF20.67
Sell
-20.88%
Downside
Reiterated
08/04/26
GlaxoSmithKline (GSK) Receives a Sell from Barclays
J.P. Morgan Analyst forecast on CH:GS71
Zain Ebrahim
J.P. Morgan
J.P. Morgan
CHF18.49
Sell
-29.20%
Downside
Reiterated
08/04/26
J.P. Morgan Sticks to Their Sell Rating for GlaxoSmithKline (GSK)
Bernstein Analyst forecast on CH:GS71
Justin Smith
Bernstein
Bernstein
CHF30.73→CHF32.74
Buy
25.35%
Upside
Reiterated
08/03/26
Bernstein Sticks to Their Buy Rating for GlaxoSmithKline (GSK)
DZ BANK AG Analyst forecast on CH:GS71
Elmar Kraus
DZ BANK AG
DZ BANK AG
―
Hold
―
Reiterated
07/29/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Crispr Therapeutics AG (NASDAQ: CRSP) and GlaxoSmithKline (LSE: GB:GSK)
Citi Analyst forecast on CH:GS71
Graham Parry
Citi
Citi
CHF22.84
Hold
-12.55%
Downside
Reiterated
07/29/26
Citi Sticks to Their Hold Rating for GlaxoSmithKline (GSK)
Bank of America Securities Analyst forecast on CH:GS71
Sachin Jain
Bank of America Securities
Bank of America Securities
CHF25.56
Hold
-2.13%
Downside
Reiterated
07/28/26
GSK: Hold Rating Reaffirmed as Near-Term Strength Offsets Long-Term Uncertainties; 2,350p Price Target Maintained
Goldman Sachs Analyst forecast on CH:GS71
Rajan Sharma
Goldman Sachs
Goldman Sachs
CHF20.34→CHF20.56
Hold
-21.29%
Downside
Reiterated
07/28/26
GSK: Solid Quarter but Modest Outlook Prompts Hold Rating and Price Target Lift to £18.90
Jefferies Analyst forecast on CH:GS71
Michael Leuchten
Jefferies
Jefferies
CHF27.19
Buy
4.11%
Upside
Reiterated
07/28/26
Jefferies Sticks to Its Buy Rating for GlaxoSmithKline (GSK)
UBS Analyst forecast on CH:GS71
Matthew Weston
UBS
UBS
CHF21.1
Hold
-19.21%
Downside
Reiterated
07/13/26
UBS Remains a Hold on GlaxoSmithKline (GSK)
Guggenheim Analyst forecast on CH:GS71
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
―
Hold
―
Reiterated
07/09/26
Guggenheim Remains a Hold on GlaxoSmithKline (GSK)
HSBC Analyst forecast on CH:GS71
Rajesh Kumar
HSBC
HSBC
CHF16.32→CHF20.23
Hold
-22.54%
Downside
Upgraded
07/06/26
GSK upgraded to Hold from Reduce at HSBCGSK upgraded to Hold from Reduce at HSBC
Intron Health Analyst forecast on CH:GS71
Unknown Analyst
Intron Health
Not Ranked
Intron Health
CHF21.76
Hold
-16.71%
Downside
Upgraded
06/10/26
GlaxoSmithKline (GSK) was upgraded to a Hold Rating at Intron Health
Kepler Capital Analyst forecast on CH:GS71
Nicolas Pauillac
Kepler Capital
Kepler Capital
CHF27.37
Buy
4.78%
Upside
Upgraded
05/26/26
Positive Report for GlaxoSmithKline (GSK) from Kepler Capital
Berenberg Bank Analyst forecast on CH:GS71
Kerry Holford
Berenberg Bank
Berenberg Bank
CHF21.75
Hold
-16.71%
Downside
Reiterated
05/05/26
GlaxoSmithKline (GSK) Receives a Hold from Berenberg Bank
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
TNYATenaya Therapeutics
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering GlaxoSmithKline

3 Months
Justin SmithBernstein
Success Rate
12/22 ratings generated profit
55%
Average Return
+1.73%
Copying Justin Smith's trades and holding each position for 3 Months would result in 54.55% of your transactions generating a profit, with an average return of +1.73% per trade.
1 Year
Michael LeuchtenJefferies
Success Rate
19/30 ratings generated profit
63%
Average Return
+5.03%
Copying Michael Leuchten's trades and holding each position for 1 Year would result in 63.33% of your transactions generating a profit, with an average return of +5.03% per trade.
2 Years
Justin SmithBernstein
Success Rate
14/22 ratings generated profit
64%
Average Return
+9.91%
Copying Justin Smith's trades and holding each position for 2 Years would result in 63.64% of your transactions generating a profit, with an average return of +9.91% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GS71 Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
0
0
0
0
1
Buy
10
7
8
9
6
Hold
21
19
25
28
22
Sell
21
18
16
16
16
Strong Sell
0
0
0
0
0
total
52
44
49
53
45
In the current month, GS71 has received 7 Buy Ratings, 22 Hold Ratings, and 16 Sell Ratings. GS71 average Analyst price target in the past 3 months is 23.36.
Each month's total comprises the sum of three months' worth of ratings.

GS71 Financial Forecast

GS71 Earnings Forecast

Next quarter’s earnings estimate for GS71 is CHF0.57 with a range of CHF0.52 to CHF0.62. The previous quarter’s EPS was CHF0.55. GS71 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 46.32% of the time in the same period. In the last calendar year GS71 has Performed in-line its overall industry.
Next quarter’s earnings estimate for GS71 is CHF0.57 with a range of CHF0.52 to CHF0.62. The previous quarter’s EPS was CHF0.55. GS71 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 46.32% of the time in the same period. In the last calendar year GS71 has Performed in-line its overall industry.

GS71 Sales Forecast

Next quarter’s sales forecast for GS71 is CHF9.70B with a range of CHF9.53B to CHF9.87B. The previous quarter’s sales results were CHF9.17B. GS71 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 31.16% of the time in the same period. In the last calendar year GS71 has Performed in-line its overall industry.
Next quarter’s sales forecast for GS71 is CHF9.70B with a range of CHF9.53B to CHF9.87B. The previous quarter’s sales results were CHF9.17B. GS71 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 31.16% of the time in the same period. In the last calendar year GS71 has Performed in-line its overall industry.

GS71 Stock Forecast FAQ

What is CH:GS71’s average 12-month price target, according to analysts?
Based on analyst ratings, GlaxoSmithKline’s 12-month average price target is 23.36.
    What is CH:GS71’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:GS71, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is GlaxoSmithKline a Buy, Sell or Hold?
        GlaxoSmithKline has a consensus rating of Hold, which is based on 3 buy ratings, 9 hold ratings and 2 sell ratings.
          What is GlaxoSmithKline’s share price target?
          The average share price target for GlaxoSmithKline is 23.36. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is CHF32.74 ,and the lowest forecast is CHF18.49. The average share price target represents -10.58% Decrease from the current price of CHF26.12.
            What do analysts say about GlaxoSmithKline?
            GlaxoSmithKline’s analyst rating consensus is a Hold. This is based on the ratings of 14 Wall Streets Analysts.
              How can I buy shares of GlaxoSmithKline?
              To buy shares of CH:GS71, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.